Skandinaviska Enskilda Banken Ab (Publ) Vaxcyte, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 9,350 shares of PCVX stock, worth $304,249. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,350Holding current value
$304,249% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
344Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$397 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$392 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$383 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$323 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$209 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.93B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...